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ABSTRACT         
Background: First line regimens give patients the best chance of long-term treatment success. It 
is imperative that patients stay on their original first line regimens to ensure program viability. 
As the ART programme matures in Namibia the proportion of patients who have had their first 
line regimens modified continues to increase. It is estimated that 3.1% of adults in Namibia are 
on second line regimens. Second line or other modified regimens are generally reserved for 
clinical, immunological or virological failure and toxicity related complications. These modified 
regimens often involve a higher pill burden, more toxicities and are often more expensive. A 
more detailed understanding of the factors associated with first line regimen modification could 
allow healthcare providers in Namibia to target these factors for intervention to reduce regimen 
modification and improve treatment outcomes. 
Methodology: This quantitative descriptive retrospective cohort study sought to describe factors 
associated with first line HAART regimen modification in treatment naïve adult patients who 
started HAART at Gobabis State Hospital between 1
st
 January 2007 and 31
st
 December 2010. 
Utilizing data from an existing electronic patient management system, quantitative methods were 
used to assess the prevalence, reasons and factors associated with first line HAART regimen 
modification. 
Results: The prevalence of HAART regimen modification was 14.1%. Treatment toxicity was 
the major reason (35%) for HAART regimen modification and this was largely due to D4T 
containing regimens. This was followed by treatment modification due to concurrent TB disease 
(27.3%), new drug availability (19%), pregnancy (6.6%) and virological failure (2%). A death 
rate of 9% was recorded by the end of the study period in each of the two groups, of those who 
had their first line HAART regimen modified and those who remained on original regimens 
respectively. There were statistically significant associations between regimen modification and 
type of regimen, care entry point, duration from HIV diagnosis to entry into HIV care, sex and 
functional status. Regimen modifications resulted in more AZT and TDF based regimes while 
88.7% of patients had D4T taken off their HAART regimens.   
Conclusions: HAART regimen modification at Gobabis State hospital is lower than in other 
settings was largely due to treatment toxicity. The death rate is high and warrants further 
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exploration. Regimen modifications resulted in more AZT and TDF based regimes and more 
patients had D4T taken off their HAART regimens.  
Recommendations: Patients still on D4T need close monitoring for side effects associated with 
this drug and should be promptly changed if this is the case. This study raises the important 
programmatic issue of the need for good data collection practices. HIV positive patients who are 
pregnant and those with concurrent TB disease need close monitoring to ensure that HAART 
regimens are modified appropriately.
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CHAPTER 1-INTRODUCTION 
1.1 INTRODUCTION 
Namibia, with an estimated total population of 2.2 million, faces a mature generalized HIV 
epidemic which is primarily heterosexually transmitted (MOHSS, 2010). It is estimated that the 
adult HIV prevalence is 13.1%, giving a total of 178 000 people estimated to be living with HIV 
(UNAIDS 2010; MOHSS 2010).  
As part of its multifaceted response to the epidemic, Namibia has been implementing an 
antiretroviral (ARV) programme in the public sector for the past eight years (Kangudie, 2008). 
Treatment with highly active antiretroviral therapy (HAART) started with six pilot hospitals in 
2003. This was rapidly rolled out to involve all thirty four state hospitals in Namibia. In March 
2011 it was estimated that about 92 000 HIV-infected adults and children were receiving ART in 
Namibia (MOHSS, 2011). This gave estimated coverage rates of 88% and 95% of adults and 
children respectively who qualified for HAART based on the CD4 <200 criteria.  
Despite the high coverage of ART in Namibia a number of challenges currently affect 
programme implementation. According to UNICEF (2011), the high cost of the ART programme 
in an era of decreasing external funding coupled with inadequate human resources and technical 
capacity to run the program are some of the challenges. It is thus necessary to keep the HIV 
treatment program affordable and simple to manage through ensuring that patients remain on 
their first line regimens. Furthermore, it is necessary to monitor the percentage of patients 
starting therapy who are prescribed an appropriate first line at site level. This ensures rational 
drug use and therefore helps in preserving first line antiretroviral medicines 
First line regimens give patients the best chance of long-term treatment success (MOHSS, 2010). 
As the programme matures more patients have had their first line regimens modified. It is 
estimated that 3.1% of adults in Namibia are on second line regimens (Niaz & Ongeri, 2011). 
Second line or other modified regimens are generally reserved for cases where there is 
documented clinical, immunological or virological failure and toxicity related complications. 
These modified regimens often involve a higher pill burden, more toxicity related complications 
are often more expensive. It is thus imperative that most patients stay on their initial first line 
regimens to ensure program viability. A more detailed understanding of the factors associated 
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with first line regimen modification could allow healthcare providers in Namibia to target those 
factors for intervention to reduce regime modification and improve treatment outcomes. 
1.2 STUDY SETTING 
This study was conducted at an anti-retroviral clinic at a rural district hospital in Namibia. This 
hospital is in Omaheke region located on the eastern border of Namibia and Botswana (MOHSS, 1999).  
The region covers a total area of 84 612 square kilometers and has a population density of 0.8 per square 
kilometer (GRN, 2005). Despite its huge geographical expanse of 84 612 km², Omaheke region has one 
health district, Gobabis. It has one district hospital located at Gobabis, one health centre and 10 primary 
care clinics (MOHSS, 2002). From the 2001 census, the total population for the district was estimated to 
be 68 039. It is estimated that 28 % of the population have livestock farming as their main source of 
household income (Suzman, 1995).  
The anti-retroviral clinic was the first ART clinic in this region and hence has the highest case 
load in the region. It has been offering anti-retroviral therapy to patients in Omaheke region since 
2005. It is staffed with a dedicated team of one doctor, three nurses, a pharmacist, a pharmacist‟s 
assistant, two lay counselors, a data capturer and a qualified social worker. Before starting 
HAART patients are counseled by the lay counselors and the nurses. The doctor initiates new 
patients on HAART and reviews them on subsequent visits as well. Nurses can equally review 
patients with no complications on their subsequent visits. The doctor or nurse appropriately 
codes and enters patient data onto the paper based data collection tools. This data is then entered 
into the electronic patient management system, (ePMS) by the data capturer. 
A total of 1400 patients are currently recorded as active on treatment (Niaz & Ongeri, 2011). 
90% of these patients are adults. 526 new patients were initiated on HAART in 2010 at this 
hospital. A patient who receives a positive HIV test result is referred to the hospital for 
enrolment into the general HIV wellness program and evaluated for the need to begin HAART. 
This assessment includes a complete medical history, physical examination to determine WHO 
clinical staging and other co-morbidities, a CD4 cell count, Hepatitis B Surface antigen test and a 
review of social eligibility criteria. At this first visit, all patients are registered into the electronic 
patient management system to assist with follow-up, tracking and record-keeping for overall 
programme management.  
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Patients are initiated on HAART following clinical and immunological criteria stipulated by the 
World Health Organization (WHO) and adopted by the Ministry of Health and Social Services 
(MOHSS). It is desirable for all patients to have a treatment supporter but absence of a treatment 
supporter is not a reason to deny treatment to a patient. Patients who develop treatment failure or 
treatment related toxicities have their regimens modified by the clinic staff that follows the 
National Guidelines for Antiretroviral Therapy-Third Edition. 
1.3 PROBLEM STATEMENT 
Highly active antiretroviral therapy (HAART) has dramatically improved the life expectancy of 
patients with human immunodeficiency virus (HIV) in Namibia. This has considerably reduced 
AIDS related morbidity and mortality of PLHIV (MOHSS, 2011). With 3.1% of adults in 
Namibia estimated to be on second line regimens  and patients living longer on treatment the 
number of patients who have their first line HAART regimens modified is set to increase over 
time (Niaz & Ongeri, 2011). The characteristics of these patients and factors associated with the 
HAART regimen modifications in a rural setting in Namibia are largely unknown. Knowing why 
patients modify therapy could improve our understanding of successful HAART, guide decisions 
regarding initiation and management of HAART in specific patient populations such as rural 
settings. This will help institutions formulate strategies to reduce HAART modification and 
improve treatment outcomes (Cesar et al, 2010). 
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CHAPTER 2-LITERATURE REVIEW 
2.1 Addressing the problem of HIV 
The human immunodeficiency virus (HIV) epidemic remains a major global public health 
challenge, with an estimated 33.4 million people living with HIV worldwide. In 2008 alone, 2.7 
million people were newly infected with HIV (WHO, 2010). While Sub-Saharan Africa is home 
to just over 10% of the world‟s population, it accounts for 68% of the global prevalence of HIV 
(UNAIDS, 2005; UNAIDS, 2010). In response to this public health problem countries in Sub-
Saharan Africa started rolling out and scaling up provision of ART in the public sector. This 
rapid scale up of ART  has been one of the success stories of sub-Saharan Africa in response to 
the HIV pandemic with  coverage having increased from about 2% in 2003 to more than 40%  
five years later (Harries et al, 2010).  
2.2 Successes and challenges in the scale up of HAART 
Introduction of HAART has turned a formerly fatal infectious disease into a treatable condition. 
Benefits of HAART include suppressing the viral load leading to restoration of immune function. 
This helps prevent the development of opportunistic infections (Martison et al, 2003; Gentile, 
2008). UNAIDS defines universal access to antiretroviral therapy as providing antiretroviral 
therapy to at least 80% of patients in need. As of December 2009, globally eight low- and 
middle-income countries had already achieved universal access and 21 additional countries had 
coverage rates higher than 50% (UNAIDS, 2010).  Access to antiretroviral therapy in low- and 
middle-income countries increased from only 400 000 people receiving therapy in 2003 to 5.25 
million by the end of 2009 (UNAIDS, 2010). This led to AIDS-related deaths dropping by 19% 
globally over the period 2004 to 2009. Another key result is a 19% decline in new HIV 
infections globally over the past decade. 
While it is important to put qualifying patients on HAART, this action alone should not divert 
attention and funds away from other more fundamental political, social, and economic needs of 
these patients. These often determine whether patients continue, discontinue or have their 
HAART regimens modified. This has been a major challenge for HIV programs in Africa 
(McCoy et al., 2005). Data from countries with patients on HAART show that most patient 
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attrition occurs within the first year of treatment initiation (UNAIDS, 2010). In 2009, the average 
retention rate at 12 months across low and middle-income countries was 82%, and was 
approximately the same among men and women (UNAIDS, 2010). 
Movement of patients between private and public sectors remains a challenge. These sectors 
often use different criteria and regimens for starting patients on HAART. This is often 
compounded by the presence of poorly trained providers and medical insurance companies‟ 
control of drug choices (Stevens et al, 2004). 
The recommended standard treatment guidelines have been evolving over the years as more 
evidence surfaced. One major recent change was the raising of the CD4 threshold below which 
patients should be started on HAART. Based on the new criterion for treatment initiation (CD4 
cell count of  below 350 cells/mm3), antiretroviral therapy coverage at the end of 2009 was 36% 
in 2009 compared to 52% if the previous criterion was used (UNAIDS, 2010). This does not only 
have financial implications on the cost of providing drugs but also stretches the service providers 
who are already overburdened (Van Damme, 2006). In another study, Smith (2005) projects that 
if countries like Zambia and Mozambique were to scale up ART for all clinically eligible 
patients they would require up to 4 times as many doctors. This is a challenge that besets many 
African nations including Namibia which may ultimately affect adequate patient monitoring to 
help keep patients on their HAART regimens. 
 
2.3 Adherence to HAART and strategies to improve adherence 
Adherence to antiretroviral therapy is fundamental to treatment success in patients living with 
HIV. Good adherence has been strongly correlated with viral suppression, reduced rates of 
resistance, increased survival, and improved quality of life (Chesney, 2006; WHO, 2003). On the 
contrary low levels of treatment adherence can be as a result of insufficient community and 
patient preparation, erratic and unsustainable drug supplies, and inadequate training and support 
of health care providers (McCoy et al., 2005). Bhat et al (2010) classify poor adherence under 
demographic, psychosocial and medication-related factors. These factors include treatment side 
effects, complex regimens, lack of social support, and feeling depressed or overwhelmed.  Poor 
adherence ultimately leads to the development of drug resistance (Mills et al, 2006). 
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Development of drug resistance consequently leads to HIV treatment regimen modification if 
patient remains on treatment. This often has long term cost implications on HIV programmes.  
 
National treatment programmes can use various strategies to ensure good adherence to HAART. 
Patient recall methods using structured self report or visual analog scales can be used to measure 
adherence and has been found to be valid and reliable in a systematic review of 77 studies done 
by Simoni et al, (2006). Additionally, pill counts and pharmacy records of medication refills can 
also be used to assess adherence and target adherence support (Grossberg, 2007; Bisson et al, 
2008; Saberi et al, 2008). The clinic needs to have a functional appointment and patient contact 
system. This helps in patient follow-up when necessary (Forster et al, 2008). The patient‟s social 
networks play a pivotal role in ensuring good adherence to treatment (Nachega et al, 2010). 
These social networks include peer support groups and peer educators. Other innovative 
interventions to improve adherence include radio announcements reminding patients to take their 
medication, ART stations at work places, and pick-ups of prepackaged ART from local general 
supply stores, schools, or community-based ART refill sites rather than always from the clinic 
(Harries et al, 2010). However, a good supply chain logistical network needs to be established 
before some of these interventions can be implemented. 
 
2.4 Modification of first line HAART regimens: Problems of treatment failure 
and toxicity 
First line regimens give patients the best chance of long-term treatment success (MOHSS, 2010). 
(see Appendix  4 & 5 for classes of antiretroviral agents and recommended HAART regimens in 
Namibia respectively). ART regimens need to be as non-toxic and simple to take as possible 
(Renaud-Thery et al, 2007). Thus, modifying therapy is to be avoided wherever possible. 
Modification of a HAART regimen can be defined as any alteration of one or more components 
of a patient‟s regimen, (Kumarasamy, 2006). As found in a South African study usage of simple 
first line regimens results in similar virologic outcomes compared to the highly individualized 
approach in developed countries (Keiser et al, 2008). National HIV treatment programs should 
thus aim to keep most of their patients on first line regimens. In a prospective study done to 
determine rates and causes of switching from first to second-line antiretroviral treatment 
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regimens in a large treatment-naive cohort in  South Africa, 96% patients remained on first-line 
therapy  while 1.7% switched to second-line regimens due to hypersensitivity reactions  or lactic 
acidosis over 760 person-years of observation (Orrell et al, 2008).  HAART may need to be 
modified but there must be a very good reason for doing so. Reasons for changing include 
treatment failure, toxicity, availability of newer and improved regimens and emergence of other 
concurrent illnesses such as TB (Bartlett & Gallant, 2004; WHO, 2004; MOHSS, 2010). 
Unregulated use of ART may also lead to the emergence of resistant viral strains (Gallant, 2008). 
This leads to treatment failure necessitating regimen modification and limiting future therapeutic 
options.  In the country Gabon, Vergne et al, (2002) showed that 58% of patients who had 
received unsupervised HAART without adequate health infrastructure developed major 
resistance mutations. 
Most often HAART regimens are modified due to toxicity related events (Lugassy et al, 2010). 
Antiretroviral toxicities can occur in a wide range from mild and self-limiting to long-term and 
disabling such as D4T-associated peripheral neuropathy. Potentially fatal complications such as 
NRTI-associated lactic acidosis can also occur (Spencer, 2005).  Some toxicities are drug class 
related while others are related to one particular ARV. The frequency and severity of class-
related toxicities also vary among the medicines within the same class. 
  
2.5 Considerations when modifying or stopping HAART 
When an ARV regimen must be modified or stopped due to intolerance or toxicity, simple 
substitution of the offending agent with another ARV in the same class may be done without 
stopping the entire treatment. In cases of severe or life-threatening toxicity all ARVs must be 
stopped. These complications include peripheral neuropathy, lactic acidosis and lipoatrophy or 
lipodystrophy (Akileswaran et al, 2005; Fellay et al, 2001). Measures should be taken to prevent 
resistance from developing. This is because HIV develops resistance quickly when there are 
insufficient blood and tissue levels of antiretroviral medications (Bartlett & Gallant, 2004). 
In conclusion, monitoring and optimally managing patients requiring HAART regimen 
modification requires adequate skill. This requires adequate human resources and staff training 
(Forster et al. 2008). This also entails strengthening the medical records systems. All the 
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foregoing factors combined will help minimize first line HAART regimen modification and keep 
future options for patients open as patients live longer on treatment. 
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CHAPTER 3 - METHODS 
3.1. Study Aim and Objectives 
3.1.1 Aim of the study 
Overall, this study aims to describe the factors associated with first line highly active 
antiretroviral therapy (HAART) regimen modification in treatment naïve adult patients at 
Gobabis District Hospital. 
3.1.2 Objectives of the study: 
i. Describe the prevalence of regime modification in adult patients 
ii. To describe the characteristics of adult patients who had their first line HAART 
regimens modified and those who did not. 
iii. To describe the factors associated with first line HAART regimen modification in adult 
patients at Gobabis District Hospital. 
 
3.2. Study Design 
A quantitative descriptive retrospective cohort study was used. Using data from an existing 
electronic patient management system (ePMS) the cohort of adult patients who started HAART 
at Gobabis State Hospital between 1
st
 January 2007 and 31
st
 December 2010 was analyzed.  
Quantitative methods were used to assess the prevalence and factors associated with first line 
HAART regimen modification in HIV positive adults. Those who had their regimens modified 
were compared with those who did not have their regimens modified. A cohort study was chosen 
because there was an existing electronic data set. It was thus cheaper and less time consuming 
for the researcher. Furthermore a cohort study is suitable when the population at risk is a well-
defined group such as this one of adult patients who started HAART at Gobabis State Hospital 
between 1
st
 January 2007 and 31
st
 December 2010.  A cohort study also provides a most direct 
measurement of the absolute risk. 
Ethical approval was sought from the University of the Western Cape (UWC) Ethical Committee 
and from the Ministry of Health and Social Services (MOHSS) of Namibia. 
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3.3 Study Population 
In this study, the study population was all adult patients (15 years and above) who started 
HAART at Gobabis State Hospital between 1
st
 January 2007 – 31st December 2010. A total of 
1407 patients were initiated on HAART during this period. HAART modification in this study 
referred to any alteration of one or more components of the patient‟s initial drug regimen  
 
The following two groups were considered for comparison in the study: 
 those who remained on original 1st line regimen during the study period  
 those whose original regimens were modified during the study period  
Table 1 below shows the inclusion and exclusion criteria used for the two groups. 
Table 1: Inclusion and exclusion criteria 
Those who remained on original 1
st
 line 
regimen  
Those whose original regimens were 
modified  
Inclusion criteria 
 Treatment naïve adults 15 years  and 
above 
 Started 1st line HAART between 1st 
January 2007 – 31st December 2010 
 Had at least one follow-up visit after 
starting HAART 
 Remained on original 1st line regimen 
throughout the study period or up to a 
recorded outcome point (dead/ 
transferred out/ lost to follow up/ status 
unknown) 
Inclusion criteria 
 Treatment naïve adults 15 years  and 
above 
 Started 1st line HAART between 1st 
January 2007 – 31st December 2010 
 Had at least one follow-up visit after 
starting HAART 
 Had  original 1st line regimen modified 
during the study period or up to a 
recorded outcome point (dead/ 
transferred out/ lost to follow up/ status 
unknown) 
Exclusion criteria 
 Patients < 15 years of age 
 Previous exposure to HAART 
Exclusion criteria 
 Patients < 15 years of age 
 Previous exposure to HAART 
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including PMTCT or PEP including PMTCT or PEP 
 
3.4 Sampling and Sample size 
All adult patients (15 years and above) who started HAART at Gobabis State Hospital between 
1
st
 January 2007 – 31st December 2010 and meeting the study criteria mentioned above were 
taken.  
3.5 Data Collection 
Selected patient data as listed on the structured data collection tool in appendix 1 was extracted 
from an existing Microsoft Excel based electronic ART patient monitoring system (ePMS) 
database kept at Gobabis State hospital. This electronic database has been in use at the facility 
since 2005. It is the main electronic reporting system for HIV patient care in Namibia. The 
source of the data for the system is the paper based ART patient care booklet which is completed 
by doctors and nurses at each patient encounter. This paper based tool has been in use since 
2003. 
Relevant data under the following categories was abstracted from the electronic system: 
demographic data, baseline laboratory findings, initial HAART regimen, treatment modification 
history, reason for modification and follow-up laboratory findings. Data cleaning then followed 
which involved removing meaningless and correcting inconsistently entered data fields. At this 
stage it was realized that some of the desired variables were missing from the database. These 
variables included adherence, blood test results such as viral load, hemoglobin, ALT (a liver 
enzyme), creatinine, hepatitis B surface antigen, TB status at HAART initiation and history of 
opportunistic infections. According to the ePMS handbook used for training data capturers in 
Namibia these variables are supposed to be entered into the system for each patient.  Thus, it 
would have been ideal for the researcher to refer to the original paper based clinical records but 
this was not possible. 
 
3.6 Definitions and descriptions of variables  
3.6.1 Definitions 
Treatment naïve: Refers to someone who has never used antiretroviral HIV drugs. 
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HAART regimen modification: Regimen modification was defined as any alteration of one or 
more components of a patient‟s regimen in this study. This definition broadly encompassed 
single, dual or whole regimen change often described as substitution or switching in other 
studies. HAART regimen modification was based on the principles of the Namibian national 
ART guidelines. Recommended HAART regimens in Namibia consist of a combination of 2 
NRTIs plus an NNRTI or a boosted PI. Considerations in the selection of regimens include 
potency, side-effect profile, the potential for maintenance of future treatment options, 
convenience of the regimen (pill burden, frequency of intake, absorption), coexistent conditions 
(e.g. TB and hepatitis B), pregnancy, use of other medications and potential medication 
interactions. Individuals who cannot be maintained on the recommended regimens are supposed 
to have their regimens modified accordingly. 
Adult patient: Adult patients were defined in this study as any patient with age equal to or 
greater than 15 years. This was an operational definition based on the fact that the HAART 
program in Namibia recognizes any patient with age equal to or greater than 15 years as an adult. 
3.6.2 Definition of variables  
The variables used in this study are defined in Table 1 below. 
Table 2: Definition of variables 
Variable Definition 
Age Patient‟s age defined  as the interval in years between the date of birth to the 
date of starting HAART in years 
Weight  Used in this study as the patient‟s weight in kilograms at starting HAART 
Sex  Used to define whether patient was male or female 
Marital status Used in this study to identify whether patient is married or not married. „Not 
married‟ included statuses recorded in the database as single, widowed, 
married or divorced 
Care entry point 
 
Describes care entry points where patient was referred from. It included the 
following categories: 
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Medical = referred from hospital in-patient services including TB 
ward/clinic. 
PMTCT = from antenatal care clinic through the prevention of  mother to 
child transmission program. 
Self referral = enrolled into care by own arrangement rather than being 
referred by a provider 
Private sector = referred from private medical providers 
Transfer in = Refers to a patient who has been receiving ART at one facility 
in the country who transfers into another in the same system with records. 
Other = not meeting any of the criteria above 
CD4 count at 
HAART 
initiation 
Patient's absolute CD4 count per mm
3
 of blood. In this study the absolute 
CD4 count at HAART initiation was used. 
Clinical stage at 
HAART 
initiation 
Clinical stage of HIV disease of the patient using the WHO staging system. 
It classifies HIV disease into four clinical stages, 1 – 4 with stage 1 being 
mild HIV disease and 4 being severe HIV disease. In this study only the 
clinical stage at initiation of HAART was used.  
Treatment 
Supporter 
A buddy chosen by the patient before starting HAART. This could be 
someone at home, in the community or at the workplace, who can 
accompany the patient to visits and assist with daily adherence to HAART. It 
is desirable that all patients have a treatment supporter. Absence of a 
treatment supporter however is not a reason to deny treatment to a patient. 
The name of the treatment supporter is entered into the database. Where no 
name was entered it was assumed that the patient had no treatment supporter 
for purposes of this study. 
Duration from 
HIV diagnosis 
to enrolment 
This was the time interval in months between the date of HIV diagnosis and 
the date of enrolling into pre-ART care. This is derived from the two dates as 
recorded in the electronic register. 
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into HIV Care   
Alive at end of 
study period 
This variable assessed whether patient was alive as of 31
st
 Dec 2010. Patients 
who had died or reported as dead had their date of death recorded in the 
system. Where no date of death was recorded, it was assumed that the patient 
was alive as of 31
st
 December 2010 
Ever put on 
CTX  
 
Cotrimoxazole (CTX) reduces the risk of death and hospitalization of 
persons with HIV. Daily cotrimoxazole prophylaxis is recommended for 
persons with HIV and either WHO Clinical Stage 3 or 4 disease or any WHO 
clinical stage with a CD4 cell count ≤ 350. The cotrimoxazole status of 
patients was recorded in the electronic database. 
Functional 
Status at 
HAART 
initiation 
 
This variable describes the functional status of the patient HAART initiation. 
Patients were put in to the following categories:  
Working = Able to work; go to school, do housework, or farming 
Ambulatory = Able to perform activities of daily living but not able to work 
or play.  
Bedridden = Not able to perform activities of daily living. 
HAART 
regimens 
The highly active antiretroviral drug combination the patient was taking. 
These are recorded in the system using standard abbreviations. 
Reason for 
HAART 
Regimen 
Modification 
This variable indicates the reason given in the electronic record or in the 
patient clinical notes why the patient had his/her HAART regimen modified. 
The following reasons were used:  
Toxicity = Drug-related adverse events which may be acute, sub acute, or 
late. If a change in a regimen is needed because of toxicity and the toxicity is 
related to an identifiable medication in the regimen, the offending medicine 
can be replaced with another medicine that does not have the same side-
effects. 
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New drug available = modification of HAART regimen done because of 
change in national guidelines recommending one drug over another. 
Pregnancy = applies to women who had regimens modified when they  fell 
pregnant and had to be put on pregnancy friendly regimens.  
TB = regimen modified due to concurrent TB disease and patient has to take 
both TB treatment and HAART. Only certain HAART regimens can be used 
in combination with TB therapy. 
TB & toxicity = regimen modified due to both toxicity and presence of TB 
disease. It was impossible to separate the two categories as it was not clear 
from the electronic system what had started of the two complications. 
Virological failure = occurs when there is a viral load >1,000 copies/ml 24 
weeks after starting HAART or viral rebound to >1,000 copies/ml on two 
consecutive measurements after a period of viral suppression (MoHSS, 
2010). Viral load assays are recommended for patients already on treatment 
who are showing evidence of immunologic and or clinical failure.  
Other = any other reason not fitting in the above categories modification 
done to reduce pill burden, or to accommodate patient‟s work schedule 
 
3.7 Validity, Reliability and generalisability 
3.7.1 Validity  
Validity refers to the degree to which an instrument is able to measure what it is intended to 
measure (Bonita, Beaglehole &Kjellstrom, 2006). All patients who started HAART between 1
st
 
January 2007 – 31st December 2010 and meeting the rest of the study criteria participated in the 
study. Data was cleaned by examining for missing, erroneous and inconsistent entries. 
This helped reduce sampling errors and thus increase validity. This study involved using an 
existing data set which had some desired variables poorly recorded or totally missing in certain 
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instances. These variables could have been important in establishing other predictors of regime 
modification. As a result this possibly reduced the study validity. 
3.7.2 Reliability 
Reliability means the consistency or repeatability of a measure (Bonita, Beaglehole &Kjellstrom, 
2006). Different clinicians who recorded the data onto patient charts could have made coding 
errors hence causing measurement bias. Equally, the data capturers who are responsible for 
entering data from the paper based charts into the electronic system could have made errors at 
data capture further causing measurement bias. It was not possible to offer training to these 
cadres to minimize data recording and coding errors since this was a retrospective study. 
3.7.3 Generalisability 
This study took the entire cohort of patients who started HAART between 1
st
 January 2007 – 31st 
December 2010. The results may be generalized to other patients seeking treatment at this 
facility. However the findings may not be generalizable to other settings in Namibia.  
3.8 Analysis 
Data cleaning, coding and analysis : Data was obtained from the Microsft Excel based ePMS  
checked for completeness, errors and cleaned. Where missing data fields were observed an 
attempt was made to obtain the data from the paper based patient charts. The data was then 
exported  to the IBM SPSS 19 statistical software package for analysis.   Nominal data was 
coded so that it could be read by the statistical package. Descriptive and analytic statistics were 
used in the analysis. The variables for each of the two groups were put into these categories: 
background characteristics; initial HAART regimen history & regimen modification patterns.  
Respective variables from the two groups were then statistically compared. Descriptive statistics 
were applied, using frequencies and cross tabulation. Pearson and Chi-square test (χ2) were used 
to compare group characteristics and differences for categorical variables. These included 
calculating the mean, median, and standard deviation (SD) of continuous data such as CD4 count 
and the frequencies (or proportions) of categorical data such as sex or marital status. Chi squared 
statistics were used to compare proportions between clients who had their regimens modified and 
those who remained on original first line regimen.  To compare means between the two groups 
the t-test was used.  The level of significance was set at p<0.05. 
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HAART regimen modification patterns were analyzed according to NRTI back bone and NNRTI 
choice.  Further analysis was done for specific drugs to determine proportions of patients who 
initiated and remained on a specific drug against those who initiated on specific drug but later 
taken off. 
 
 
3.9 Ethical and Legal Considerations 
Ethical clearance was sought from the University of the Western Cape School of Public health in 
writing. After the protocol was ethically approved by the University of the Western Cape ethical 
clearance committee further approval sought and granted by the Ministry of Health and Social 
Services of Namibia. This is largely because this study collected information on human subjects. 
Background information on the aims of the study was given to ministry officials. The regional 
health director of Omaheke region was asked to give informed consent before the patient records 
from Gobabis District hospital were used.  
All the information collected was treated confidentially. No names were used and only codes 
were used to identify individually patient records. The computer that was used for data entry and 
analysis was password protected.  
To minimise the negative impact of the study data abstraction was carried out on less busy days 
and the researcher was respectful to the data capturers‟ and clinicians‟ time. Clinic staff who 
assisted the researcher with access to the electronic data set were reassured that their position at 
work would not be affected whether they assisted in the study or not and that should the results 
show poor practice, this would not be used in a punitive way against them. It is hoped that the 
findings and recommendations of this study will assist the management at Gobabis District 
Hospital improve the quality of care provided to patients on HAART. The study findings will be 
shared with MOHSS and a feedback meeting will be scheduled for Gobabis District Hospital 
staff.  
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CHAPTER 4-RESULTS 
This chapter describes the results of this study which was conducted to describe factors 
associated with first line HAART regimen modification in treatment naïve adult patients at 
Gobabis State Hospital. The first section presents the characteristics of the entire cohort studied. 
This is then followed by a description of the characteristics of adult patients who had their first 
line HAART regimen modified and those who remained on original regimens. The next section 
then summarizes the type of HAART regimens used, the reasons and patterns of modification. 
The summary of major findings is given at the end of the chapter. 
4.1 SAMPLE SIZE  
A total of 1407 patients meeting the study criteria were started on HAART at Gobabis State 
Hospital between 1
st
 January 2007 and 31
st
 December 2010. Of these, as shown by Figure 1, one 
hundred and ninety nine (14.1%) had their treatment regimens modified while 1208 (85.9%) 
remained on their original first line regimens.  
 
Figure 1: Pie chart showing proportions of patients who remained on original regimens and those whose 
regimens were modified. 
14.1% 
85.9% 
n=1407 
Patients who had regimens 
modified  
Patients who remained on 
original regimen 
 
 
 
 
19 
 
 4.2 REASONS FOR HAART REGIMEN MODIFICATION 
Treatment toxicity, as shown in Figure 2, was the major reason for HAART regimen 
modification as it contributed 35.3% of the patients whose regimens were modified. This was 
followed by treatment modification due to concurrent TB disease which contributed 27.3% of the 
patients who had regimens modified. Almost 19% of the patients had their regimens modified 
because of new drug availability. Pregnancy contributed 6.6% of the regimen modifications and 
modification due to virological failure contributed only 2%. 
 
Figure 2: Pie chart showing reasons for HAART regimen modification 
4.3 BACKGROUND CHARACTERISTICS FOR THE WHOLE GROUP  
The median age for all patients starting HAART at Gobabis State Hospital during the study 
period was 38 years as shown in Table 1. Only 10% of these patients were married and females 
constituted 60% of the whole cohort. The commonest care entry point into the HAART program 
was via the „medical‟ route which contributed 67%, followed by being self-referred (15%). 
Seventy percent of all the patients had treatment supporters. 
Toxicity 
35% 
TB 
27% 
New drug available 
19% 
Other 
8% 
Pregnancy 
7% 
TB & toxicity 
3% 
Virological failure 
2% 
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Table 3: Background characteristics for the whole cohort 
Characteristic Frequency (Percent) 
Age, years (median) 38.0 
Sex   n (%) 
Male 
Female 
n=1406 
561 (39.9%) 
845 (60.1%) 
Marital Status n (%) 
Married 
Not married 
n=1118 
119 (10.6%) 
999 (88.4%) 
Care Entry Point n (%) 
PMTCT 
Medical 
Private sector 
Self Referral 
Transfer in 
Other 
n=1345 
79 (5.9%) 
903(67.1%) 
3 (0.2%) 
207(15.4%) 
120 (8.9%) 
33 (2.4%) 
Presence of Treatment Supporter n (%) 
Yes 
No 
n=1406 
988 (70.3%) 
418 (29.7%) 
 
 
Figure 3, shown below, goes on to show that patients starting HAART at Gobabis State Hospital 
between 1
st
 January 2007 and 31
st
 December 2010 were largely in the 30-39 year age group. 
Only 2 patients were above 80 years of age. 
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Figure 3: Age groups for the whole cohort 
 
4.4 BACKGROUND CHARACTERISTICS FOR EACH OF THE TWO 
GROUPS 
There was a significant difference in the time from HIV diagnosis to entry into HIV care 
(p<0.0001) between patients who remained on original regimen and patients who had their 
regimens modified. As shown in Figure 4 below, a greater proportion (57.9%) of patients who 
remained on their original regimens were enrolled into HIV general wellness care during the first 
month of testing positive for HIV as compared to 44.2% of those who had regimens modified.  
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Figure 4: Duration from HIV diagnosis to enrollment into HIV general wellness care  
 
Table 2, below, shows that the median age of patients who remained on original regimen was 
37.5 years with their ages ranging from 19 to 83 years. For patients who had their regimens 
modified, the median age was 39 years and with an age range of 19 to 64 years. Males formed 
58.8% of patients who remained on original first line regimen. Proportionally there were more 
females (67.8%) among patients who had their regimens modified. Patients with single marital 
status formed the majority in both groups. Entry into HIV care via the “Medical” route was the 
commonest in the two groups of patients. Sixty-nine percent of patients who remained on 
original regimen had treatment supporters while 75% of those who modified regimens reported 
having treatment supporters. 
There was a statistically significant association between regimen modification and sex 
(p=0.016), with more men than women having altered regimens. There was also a statistically 
significant association between regimen modification and care entry point (p<0.0001) and it 
seems that this was due to the higher proportion of patients who remained on the original regime 
entering care via the „medical‟ route. The mean weight at starting HAART for patients who 
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remained on original regimen was 51.9kg and 54.1kg for patients who had their regimens 
modified with no statistically significant weight differences between the two groups ( p=0.234). 
As also shown in Table 2, there was an association between regimen modification and 
“functional status at HAART initiation” (p<0.0001).  Sixty eight percent of the patients in each 
of the groups had been on cotrimoxazole at some point during the study period and 12.1% of 
patients who remained on original regimens were bed ridden at HAART initiation as compared 
to 2.1% amongst those who had their regimens modified. Nine percent of the patients in each of 
the two groups were recorded as dead by the end of the study period. 
 
Table 4: Background and other HIV care patient characteristics of the two groups 
Characteristic Patients who 
remained on 
original regimen 
 
Patients who had 
regimens modified 
 
p value 
Age, years (median) n=1208 
37.5 
n=199 
39.0 
0.113 
Sex,   n (%) 
Male 
Female 
n=1207 
497 (41.2%) 
710 (58.8%) 
n=199 
64 (32.2%) 
135 (67.8%) 
0.016 
Marital Status, n (%) 
Married 
Not married 
n=952 
110 (11.5%) 
842 (88.4%) 
n=163 
9 (5.5%) 
154 (94.5) 
0.170 
Care Entry Point, n (%) 
PMTCT 
Medical 
Private sector 
Self Referral 
Transfer in 
Other 
n=1171 
68 (5.8%) 
822 (70.2%) 
3 (0.3%) 
156 (13.3%) 
107 (9.1%) 
15 (1.3%) 
n=174 
11 (6.3%) 
99 (56.9%) 
0(0.0%) 
51 (29.3%) 
13 (7.5%) 
0(0.0%) 
<0.0001 
Presence of Treatment    
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Supporter, n (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
Yes 
No 
n=1208
839 (69.4%) 
369 (30.6%) 
n=199
150 (75.4%) 
49 (24.6%) 
0.089
Mean weight, kilograms 
 
n=469 
51.9 
n=142 
54.1 
0.234 
Median CD4 count at 
starting HAART, cells/mm
3
 
n=1208 
154.5 
n=192 
173.0 
0.625 
Functional Status at 
HAART initiation, n (%) 
Ambulatory 
Working 
Bedridden 
 
n=1145 
52 (4.5%) 
954 (83.3%) 
139 (12.1%) 
 
n=179 
21 (11.7%) 
154 (86.0%) 
4 (2.2%) 
 
<0.0001 
Ever put on CTX ,  n(%) 
Yes 
No 
n=1206 
825 (68.4%) 
381 (31.5%) 
n=198 
135 (68.2%) 
63 (31.7%) 
0.949 
Alive at end of study period, 
n (%) 
Yes 
No 
n=1207 
 
1097 (90.8%) 
110 (9.1%) 
n=198 
 
180 (90.5%) 
18 (9.0%) 
0.954 
 
 
 
As shown below in Figure 5, 44% of patients who remained on original regimen and 58% 
percent of those whose regimens were modified had CD4 counts between 100-199 cells/mm
3
 at 
HAART initiation.  However, only 5.1% of patients whose regimens were modified had CD4 
counts less than 50 as compared to 12.3% among those who remained on their original regimens. 
There were no significant CD4 count differences (p=0.625) between the two groups of patients. 
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Figure 5: CD4 count band categories at starting HAART 
 
As shown below in Figure 6, most of the patients in both groups were in WHO clinical stage 3, 
with almost 46% of patients who had their regimens modified and 40.7% for patients who 
remained on original regimen in clinical stage 3 at HAART initiation. Furthermore, 11% or less 
of the patients were in WHO clinical stage 1 or 4 in both groups. 
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Figure 6: WHO Clinical stages of patients who remained on original regimens and those whose regimens 
were modified 
 
4.5 HAART REGIMEN HISTORY AND MODIFICATION PATTERNS  
The following is an analysis of HAART regimen history and modification patterns of patients 
who started HAART at Gobabis State Hospital between 1
st
 January 2007 and 31
st
 December 
2010. 
 
4.5.1 HAART regimens at initiation for whole cohort according to NRTI back bone 
Overall, AZT based regimens contributed the majority (53.4%) of regimens at initiation as 
shown in Figure 7. 
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Figure 7: HAART regimens at initiation for whole cohort according to NRTI back bone  
  
4.5.2 HAART regimens at initiation for whole cohort patients according to NNRTI choice 
In almost 75% of patients initiating HAART at Gobabis State hospital during the study period 
the NNRTI of choice was nevirapine. This is illustrated in the pie chart in Figure 8. 
AZT based  
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D4T based  
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TDF based  
29% 
(N=1310) 
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Figure 8: HAART regimens at initiation for whole cohort according to NNRTI choice  
 
4.5.3 HAART regimen modification patterns 
The mean time before regimen modification was 16.7 months with a standard deviation of 12.8. 
As shown in Figure 9, regimen changes have resulted in more AZT and TDF based regimes and 
less D4T based. Even in those patients who have had their regimens modified, ABC-based 
regimens were rare.  Figure 10 goes on to show that regimen modification resulted in more 
EFV and LPV-r containing regimens being used and less NVP containing regimen usage. Only 
1% of the patients were put on the standard four drug second line regimen used in Namibia. 
 
NVP based 
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EFV based 
25.5% 
(N=1304) 
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Figure 9: HAART regimens for patients who had regimens modified according to NRTI back bone 
 
 
 
 
 
Figure 10: HAART regimens for patients who had regimens modified according to NNRTI or PI choice 
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As shown in Table 5 below, the biggest proportion (88.7%) of patients had D4T taken off their 
HAART combinations. Table 5 also highlights that there was a significant association between 
regimen modification and the type of original first line regimen (p<0.0001). According to the 
cross tabulation in Table 6 the most common reason to change therapy was due to D4T toxicity 
followed by AZT toxicity. 
 
Table 5: Regimen modification according to specific drugs 
 Patients who initiated 
and remained on specific 
drug 
Patients who initiated on 
specific drug but later taken 
off 
 
p value 
 n (%) n (%)  
 
  
      <0.0001* 
AZT-based 39 (43.3) 51 (56.7) 
TDF-based 8 (66.7) 4 (33.3) 
D4T-based 11 (11.3) 86 (88.7) 
NVP 92 (55.4) 74 (44.6) 
EFV 14 (43.8) 18 (56.3) 
 
Table 6: Cross tabulation of original first line regimen versus reason to change therapy  
 Reason to change therapy 
Original 
HAART 
regimen 
New 
drug 
available 
 
Virological 
failure 
 
Pregnancy 
 
TB 
 
TB & 
toxicity 
 
Toxicity 
 
Other 
 
Total 
AZT 
based  
16 1 4 33 3 31 2 90 
D4T 
based  
21 3 8 14 0 38 12 96 
TDF 
based   
0 0 1 7 2 1 1 12 
Total 37 4 13 54 5 70 15 198 
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SUMMARY OF RESULTS 
In summary, a total of 1407 patients meeting the study criteria were started on HAART at 
Gobabis State Hospital between 1
st
 January 2007 and 31
st
 December 2010. The prevalence of 
HAART regimen modification was 14.1%. Treatment toxicity was the major reason for HAART 
regimen modification and this was largely due to D4T toxicity,  concurrent TB disease (27.3%) , 
new drug availability (19%), pregnancy (6.6%) and virological failure ( 2%). Nine percent of the 
patients in each of the two groups were recorded as dead by the end of the study period. There 
were statistically significant associations between regimen modification and type of original first 
line regimen, care entry point, duration from HIV diagnosis to entry into HIV care, sex, and 
functional status at HAART initiation respectively.    Regimen modifications resulted in more 
AZT and TDF based regimes while 88.7% of patients had D4T taken off their HAART 
regimens. Also, more EFV and LPV-r containing regimen usage was evident.  
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CHAPTER 5 – DISCUSSION 
This chapter presents the discussion of the results of the study to describe reasons and factors 
associated with first line regimen modification in treatment naïve adult patients on highly active 
antiretroviral therapy at a rural clinic in Namibia. 
5.1 PREVALENCE OF HAART REGIMEN MODIFICATION 
In this study, 14.1% of patients starting HAART had their treatment regimens modified. 
Knowing the magnitude of regimen modification is important as it provides information on the 
rate at which HAART regimens may be failing, evolving or not tolerated (Kirstein et al., 2002). 
It must be noted that different studies define HAART regimen modification differently. In this 
study modification of a HAART regimen was defined as any alteration of one or more 
components of a patient‟s regimen. This definition was similar to the definition used in the study 
done by Kumarasamy et al., (2006) in which 20% of patients modified their first-line regimen. In 
another study done in a resource limited setting in South India, 33% of the patients switched 
therapy (Chandy et al., 2011). Another study involving only women, 45.6% switched their 
HAART regimens (Kirstein et al., 2002).  A South African study found that 72% remained on 
their initial regimen after 3 years of being in an HIV care treatment programme in Cape Town 
and concluded that adult patients can tolerate their initial HAART regimen for up to 3 years 
(Boulle et al., 2007). Thus, the regimen modification prevalence at Gobabis State hospital can be 
considered lower than in other settings. 
 
5.2 REASONS FOR HAART REGIMEN MODIFICATION 
5.2.1 Treatment toxicity 
In this study, 35% of the patients whose regimens were modified were due to treatment toxicity. 
While studies define toxicity differently, toxicity remains one of the major reasons for treatment 
modification or discontinuation in various settings. An Italian study by Cicconi et al., (2010) 
discovered that intolerance/toxicity led to 58.5% of HAART discontinuation, (696 of 1189 
patients). A retrospective study done in Rio de Janeiro, Brazil involving 670 treatment-naive 
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patients who received HAART between January 1996 and December 2006 observed that 40% of 
HAART modifications were toxicity related (Cardoso et al., 2010). 
The most common reason to change therapy at Gobabis State hospital was due to D4T toxicity 
followed by AZT toxicity. It is now known that D4T is associated with serious potential 
toxicities including lactic acidosis, peripheral neuropathy and lipoatrophy (Westreich et al., 
2009). Drug toxicities also have an impact on adherence (Boulle et al., 2003).  The World Health 
Organization (WHO) now recommends that D4T should be phased out wherever possible 
(Bendavid et al., 2010). Modifying HAART regimens should be done appropriately to ensure 
good treatment outcomes such as lower death rates (Boulle et al., 2003; Subbaraman, 2003; 
Falco et al., 2002). 
5.2.2 Concurrent TB disease 
HAART regimen modification due to concurrent TB disease contributed 27.3% of the patients 
who had regimens modified. Namibia, with a case notification rate of 634 cases/100, 000 
population in 2009, has one of the highest TB case notification rates in the world (MoHSS, 
2009). While HIV is the most powerful factor known to increase the risk of TB and the benefits 
of treating HIV during TB treatment are well documented, it must be noted that multiple factors 
make it complicated to concurrently use antiretroviral and TB treatment therapy (Getahun et al, 
2009). These include drug-drug interactions, presence of immune reconstitution inflammatory 
syndrome, overlapping HAART & TB drug side effects, adherence challenges with multi-drug 
therapy for the two infections and the need for coordinated care between TB and HIV care 
providers (de Jong et al, 2004; Middelkop, 2009). A good example of why regimen modification 
may be indicated is that of the TB drug called rifampicin which is a strong inducer of the 
cytochrome p450 cytochrome liver enzyme system that substantially lowers the levels of 
nevirapine but lowers the levels of efavirenz less (Lopez-Cortes et al, 2001; Patel et al, 2004). As 
a result, the factors listed above often lead to the modification of HAART regimens. Providers 
should be mindful that pulmonary tuberculosis is a WHO Clinical Stage 3 disease and extra-
pulmonary TB is Clinical Stage 4. Thus patients with either diagnosis are eligible for HAART 
which should be initiated as soon as possible (MoHSS, 2010). 
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5.2.3 Pregnancy 
Pregnancy contributed 6.6% of the regimen modifications in this study. HIV positive pregnant 
women require HAART both for their own health and for prevention of perinatal transmission of 
HIV (MoHSS, 2010). Some HAART regimens have to be modified for fear of harming the 
unborn baby (Cooper et al, 2002). In a Botswana randomized clinical trial on antiretroviral 
regimens use in pregnancy, modification of HAART regimen occurred in 11% of women 
receiving the nevirapine, zidovudine and lamivudine combination who formed the observational 
group (Shapiro et al., 2010). The lower percentage (6.6%) of regimen modification in this study 
due to pregnancy may be due to the fact that Namibia has tended to use pregnancy friendly 
regimens as first line therapies. Healthcare workers have been trained to avoid using efavirenz or 
D4T in women of child bearing age (MoHSS, 2010).  
 It should also be noted that pregnancy is not uncommon in young women on HAART. This may 
be due to the fact that with the increasing availability of HAART and its associated improvement 
in health women in their reproductive years women may want to have children (Namale  et al, 
2007). In the DART randomized trial of ART-monitoring strategies among adults with 
symptomatic HIV infection and CD4 <200 cells/mm3 initiating ART in Kampala, Entebbe and 
Harare 9.7% women fell pregnant after a median 2.4-year follow-up (Namale  et al, 2007).  
 
5.2.4 Availability of new drugs 
Nineteen percent of the regimen modifications were due to availability of a new drug. The 
evolution of HAART regimens in Namibia is discussed in detail in section 5.3.5 on HAART 
regimen modification patterns and toxicity. Over the years, Namibia has been keeping pace with 
new recommendations from WHO in accordance with the latest evidence-based best practices 
(MoHSS, 2010). WHO now recommends HAART regimens with fewer side-effects, better 
toxicity profiles, less interactions and lower pill burden with the hope that simplified regimens 
result in savings to the health care system (WHO, 2006). These principles have resulted in 
newer drugs such as TDF being introduced into first line HAART regimens. 
 
5.2.5 Virological failure 
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Virological failure contributed only 2% of the modifications. This is low compared to other 
settings. In one study to describe the reasons for, and factors associated with, modification and 
discontinuation of HAART regimens by Mocroft et al, (2001) 44% of the patients modified their 
HAART regimen due to virological failure. Patients with virological failure usually end up on 
second line regimens. This small contribution of virological failure to regimen modification at 
Gobabis District hospital means that most patients who had regimens modified remained within 
first line regimens. 
It cannot be ruled out in this study that the low prevalence of virological failure could have been 
as a result of poor vigilance for virological failure at Gobabis State hospital. It is well 
documented that patients with higher viral loads at HAART initiation may not achieve good viral 
suppression (Mocroft et al., 2001; Ledergerber, 1999). Mandatory viral load testing at 6 months 
after initiating HAART only began in Namibia in 2008 (MoHSS, 2010). The current national 
guidelines recommend that if the viral load at 6 months is  >1000 copies/ml, the CD4 count 
should be checked, intensive adherence counseling offered to the patient  and repeat the viral 
load in 3 months (MoHSS, 2010). If this tighter protocol was in place during the time this study 
was done maybe more cases of virological failure could have been picked. 
 
5.3 FACTORS ASSOCIATED WITH HAART REGIMEN MODIFICATION 
This study highlighted that there were significant associations between regimen modification 
and sex, marital status, care entry point, duration from HIV diagnosis to entry into HIV, 
functional status and type of original first line regimen. The following subsections discuss each 
of these factors separately. 
5.3.1 Regimen type and modification patterns  
There were significant differences between first line regimen drugs for patients who stayed on 
and those whose regimens were modified (p<0.0001). The largest proportion of patients had D4T 
taken off their HAART combinations.  Consequently regimen modifications have resulted in less 
use of D4T based regimens while use of TDF and AZT based regimens has been increasing.  
These findings may not come as a surprise seeing that the most common reason for HAART 
regimen modification in this study, treatment toxicity, was largely due to D4T toxicity. To 
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understand the HAART regimen modification patterns shown in this study it is fitting to 
understand how HAART drug choices have evolved in the public sector in Namibia. 
D4T containing regimens were the commonest in the Namibia‟s public HAART program when 
the program was launched in 2002 (MoHSS, 2008). However, D4T lost favor due to the long 
term side effects associated with it which have been described above in the section on treatment 
toxicity (Westreich et al, 2009).  
The next recommended first line NRTI agent in Namibia after D4T then became AZT in 2008. 
This was short lived as the country experienced a surge in patients who developed AZT induced 
anaemia, with some even requiring therapeutic blood transfusion (MoHSS, 2010).  AZT is 
associated with bone-marrow toxicity, commonly manifesting as neutropenia or anemia 
occurring within the first 3 months of therapy (Ssali, Stöhr, Munderi et al, 2006). A study by 
Mengistu et al (2010) at Katutura Intermediate hospital in Namibia involving 5025 patients on 
HAART noted that 12.7% of the patients had substitution of their 1st line HAART regimen with 
20% being AZT replacements with other NRTIs. 
Following the challenges associated with D4T and AZT the NRTI of choice since 2010  in 
Namibia has been TDF (MoHSS, 2010). TDF also has the advantage of treating hepatitis B 
(HBV) co-infection (Bartlett & Gallant, 2005). Namibia has a high chronic HBV sero-
prevalence, estimated by the blood transfusion service to be about 15% (MoHSS, 2010). In a 
South African study, a TDF based regimen (TDF/3TC/NVP) was associated with considerably 
better health outcomes (Bendavid et al, 2010).  
In this study regimen modification resulted in more EFV containing regimens being used and 
less NVP containing regimen usage.   High TB co-morbidity in Namibia could have contributed 
to this observation. As prior discussed, EFV is the NNRTI of choice in patients who have to 
concomitantly take rifampicin as one of the drugs on their  TB regimens. HIV-infected persons 
with  latent TB infection, have a 10% risk each year of developing active TB disease (Narain et 
al, 2009). In another South African study, Boulle et al (2007) found that 8% and 2% of 
substitutions were due to nevirapine and efavirenz  toxicity respectively.  
Regimen modification also resulted in more LPV-r containing regimens being used.  This is not 
an unusual finding since LPV-r is part of standard second line regimen in Namibia (MoHSS, 
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2010). It is however important to note that only 1% of the patients were put on the standard four 
drug second line regimen used in Namibia.  This is much lower compared to the global average 
of an estimated 4% of adults on  second-line HAART (Renaud-Thery, 2007). 
 
5.3.2 Care entry point 
Entry into HIV care via the “Medical” route was the commonest in the two groups of patients, 
70% of patients who remained on original regimen and 57% of those who modified regimens 
respectively. In this study the „Medical‟ care entry point included patients entering into HIV care 
from hospital in-patient services and patients co-infected with TB referred from the TB ward and 
clinic. Apart from TB co-infection this subset of HIV positive patients normally seeks services 
for treatment of other ailments such as meningitis, diarrhea, skins conditions and psychiatric 
diseases (Mindel & Tenant-Flowers, 2001). Floyd et al (1999), in a study to assess the 
HIV/AIDS epidemic's impact on demand for inpatient hospital care in a rural area of South 
Africa concluded that the  epidemic had impacted the demand for adult tuberculosis and general 
medical care.  
The above mentioned medical conditions that cause HIV infected persons to utilize hospital 
services emphasizes the importance of providing prophylaxis for common conditions such as 
pneumocystis jiroveci pneumonia using cotrimoxazole and TB using isoniazid (Betz et al,2005). 
This finding should compel healthcare managers in Namibia to allocate more resources and 
strengthen HIV testing services at health facilities. 
5.3.3 Duration from HIV diagnosis to entry into HIV wellness care  
This study found that there was a significant difference in the duration from HIV diagnosis to 
entry into HIV care (p<0.0001) between patients who remained on original regimen and patients 
who had their regimens modified and 57.9% of patients who remained on their original regimens 
and 44.2% of those who had regimens modified respectively, were enrolled into HIV general 
wellness care during the first month of testing positive for HIV.  It is known that rapid entry into 
care and initiation of HAART carries many benefits including reduction in HIV  transmission 
(Dieffenbach et al, 2009; Granich et al, 2009; Holtgrave, 2009). The findings in this study  are 
comparable to findings from a meta analysis to estimate the proportion of HIV-diagnosed 
persons who entered into care shortly after diagnosis done by Marks et al (2010), which 
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concluded that the majority (72%) of patients entered into care at 4 weeks from diagnosis. The 
mean time before regimen modification in the meta analysis was 16 months. In another  Italian 
cohort of antiretroviral-naïve patients , 36% of patients who began a HAART regimen modified 
or discontinued their initial regimen over a median follow-up time of 11 months (Cicconi et al., 
2010).  
5.3.4 Sex  
There was a statistically significant association between regimen modification and sex 
(p=0.016), with more men than women having altered regimes. This is an interesting finding, 
though difficult to explain. In a study involving HIV positive patients above 16 years at 
the Royal Free Hospital, London it was discovered that men start HAART late and stand a higher 
chance of developing co-morbidities necessitating HAART regimen modification (Sabin et al, 
2004). A multicentre study done in clinics providing HAART in Africa, Latin America, and Asia 
comparing women and men receiving HAART concluded that women are less likely to have 
advanced HIV infection at HAART initiation (Braitstein et al., 2008).  It is possible that men 
may be starting HAART late at Gobabis State hospital. This warrants further investigation.  
On the contrary some studies have demonstrated sex related differences on likelihood of 
modifying HAART. A study done in Brazil by Cardoso et al (2010) showed that women had a 
higher hazard for regimen modification due to toxicity as compared to men. 
5.3.5 Functional status 
It was noted that patients functionally classified as „working‟ were more likely to have their 
regimens modified compared to those in the ambulatory category who are expected to have more 
advanced disease. This was contrary to findings from the study by Zhou et al (2010) in which 
advanced disease was a predictor of treatment modification. The reasons for this finding in this 
Namibian cohort warrants further exploration. 
5.4 OTHER GENERAL PATIENT CHARACTERISTICS  
Death rate: The only treatment outcome indicator described in this study was whether the 
patient was alive or dead at the end of the study period. There was a significant association 
between regimen modification and whether patient was alive or dead at the end of the study 
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period.   Nine percent of the patients in each of the two groups were recorded as dead by the end 
of the study period.  This death rate is much higher as compared to a death rate of 3.7% shown 
by a South African study (Westreich et al, 2009). HIV treatment programs need to investigate 
high rates of death among patients on HAART to determine the risk factors (Bisson et al, 2008). 
Risk factors for death found in a Botswana study which recorded high death rates of 7.1% and 
16.8% before and after patient tracing respectively were being male, low CD4 count and low 
hemoglobin levels (Bisson et al, 2008).    
Treatment supporters: Seventy percent of all the patients had treatment supporters. This should 
be commended since presence of a treatment supporter is important in ensuring good treatment 
outcomes. A qualitative study done among HIV-infected adults in South Africa highlighted the 
importance and need for treatment supporters in helping maintain good adherence (Nachega et 
al, 2006). Similarly, a study to determine the impact of treatment supporters, though in a TB 
program, in Pakistan found that patients with no treatment supporters had lower treatment 
success rate as compared to patients who had treatment supporters (Soomro et al, 2012). 
 
CD4 count: In this study the median CD4 counts were 155 and 173cell/mm
3 
 for patients who 
remained on original regimen and patients who had their regimens modified respectively. 
Contrary to the researcher‟s experience CD4 count was not found to be associated with regimen 
modification in this study. It is interesting to note that other studies discovered that regimen 
modification is actually associated with lower CD4 counts. A study by Zhou et al (2010) carried 
out among Asian patients to examine the rates and predictors of treatment modification 
discovered that advanced disease and lower CD4 count were associated with a higher rate of 
treatment modification. Similarly, Chandy et al (2011) also found low CD4 counts as a predictor 
of treatment switching. Though this study was conducted in a private hospital in Bangalore it 
was primarily based on patients from a limited resource setting similar to Namibia. It may be 
necessary to investigate further the above mentioned finding. 
5.5 LIMITATIONS 
5.5.1 Due to the broad nature of this study it was impossible to measure and investigate all 
aspects related to HAART regimen modification at this hospital. As such this study may 
not be able to adequately explain some of the reasons why patients have their regimens 
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modified since it was based on records review. Consequently some of the qualitative 
aspects of the reasons why HAART regimens were modified or discontinued were not 
addressed by this study. Information obtained from this study can best be used to describe 
prevalence of regimen change at this facility.  
5.5.2 Use and analysis of routine data is never without challenges. This study was affected by 
one of the challenges of retrospectively utilizing electronic databases, that of missing, 
inconsistent and meaningless data fields. Only factors which were properly documented 
in the electronic data system were included in the study. The following variables had to 
be excluded from the original data collection tool because they were not well 
documented: adherence, weight, blood test results such as viral load, hemoglobin, ALT 
(liver enzyme), creatinine, hepatitis B surface antigen, TB status at HAART initiation and 
history of opportunistic infections. Contrary to expectations, all these fields were blank. 
Only the CD4 counts were consistently recorded in the electronic records. While this may 
indicate poor patient access to laboratory testing services this could just have been poor 
data collection practices. 
5.5.3 The challenges above could have been circumvented by referring to the paper based 
records. It was difficult getting access to the paper based records of the affected 
electronic records. Some of these records had been moved to peripheral clinics as the 
program had been decentralized as part of the Integrated Management of Adulthood 
Illnesses (IMAI). Furthermore, due to increasing number of records over the years, some 
records could have just been poorly filed or moved with patients who transferred out. All 
these issues made data collection, cleaning and analysis a mammoth task. Good data sets 
are essential for accurate interpretation of HIV treatment program trends. 
5.5.4 This study was carried out using data from patients accessing HAART from a 
government health facility. This may not be truly reflective of the entire population since 
a significant proportion of Namibians currently access HAART from the private sector. 
5.5.5 This study was carried out using data collected over a three year period. The prevalence 
and risk factors associated with HAART regimen modification could have varied greatly 
over this period depending on drug availability, changes in national policies and 
guidelines on HIV treatment. For example declining use of D4T from 2008 in first line 
regimens is expected to reduce modifications due to drug toxicity. 
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5.5.6 This study had a small sample size and not fully representative of all adult patients on 
highly active antiretroviral therapy in Namibia. Therefore the study findings cannot be 
generalized to all HIV positive adult patients in Namibia.  
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CHAPTER 6 – CONCLUSION AND RECOMMENDATIONS 
6.1 CONCLUSION 
The study investigated the factors associated with first line regimen modification in treatment 
naïve adult patients on highly active antiretroviral therapy at a rural clinic in Namibia. The 
results revealed that HAART regimen modification at Gobabis State hospital is lower than in 
other settings. Though other treatment outcomes were not studied the death rate among patients 
on HAART at Gobabis State is high and warrants further exploration.  
The commonest reason for HAART regimen modification was toxicity largely due to  D4T 
followed by modification due to TB/HIV co-infection. Furthermore, the fact that HAART 
regimens were modified due to pregnancy considerations highlights the need to continuously 
ensure that women of reproductive age should always be put on pregnancy friendly regimens. 
Factors associated with regimen modification were type of regimen, care entry point, duration 
from HIV diagnosis to entry into HIV care, sex and functional status. There is need to explore 
how other factors such as viral load, ALT, haemoglobin and adherence impact HAART regimen 
modification.  
6.2 RECOMMENDATIONS 
The following recommendations can be drawn from this study 
 This study raises the important programmatic issue of good data collection practices. 
Electronic data records need to be complete in order for them to be useful in interpreting 
program trends. Closer supervision of data clerks is recommended and there should be 
more defined quality control checks directed from the national level. High patient loads, 
high staff turnover and less than optimal staff supervision often compound this problem. 
These need to be addressed if applicable. 
 Any patients still on D4T need closing monitoring for side effects associated with this 
drug and should be promptly changed if this is the case. 
 TB and HIV co- infection are the second most prevalent reason for regimen modification. 
It is encouraged that health care workers implement good monitoring of patients on either 
or both treatments of each of these diseases in order to get good treatment outcomes. The 
care and appropriateness of HAART regimens being used in women at Gobabis State 
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hospital needs close scrutiny since this study showed that some women had regimens 
modified because of pregnancy.    
 A further study to determine the predictors of regimen modification is encouraged. 
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APPENDICES  
APPENDIX 1- Data collection tool  
Table 7: Data collection tool 
Code number:     Date: 
Demographic information 
1. Sex:  [1] Male 
[2] female 
2. Date of birth (dd/mm/yy)                    
3. Marital status 
 
[1] Not married 
[2] Married 
 
4. Care entry point 
 
[1] PMTCT 
[2] Medical 
[3] Private sector 
[4] Self referral 
[5] transfer in  
[6] Other 
5. Treatment supporter 
 
[1] Yes 
[2] No 
Background clinical and laboratory findings  
6. Date of HIV diagnosis 
 
            
7. Date of enrolment into general HIV 
wellness care  
                 
8. Date HAART started               
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9. Clinical stage when eligible for HAART 
 
[1] 1 
[2] 2 
[3] 3 
[4] 4 
10. Weight at start ART            kilograms, (to one decimal place) 
11. Functional status at start ART  [1] Working 
[2] Ambulatory 
[3] Bed ridden 
12. CD4 at start ART          Cells/mm3 
13. Did patient receive cotrimoxazole 
prophylaxis? 
[1] Yes 
[2] No 
ARV regimen history  
14. HAART regimen at start  [1] D4T/3TC/NVP 
[2] D4T/3TC/EFV 
[3] AZT/3TC/NVP 
[4] AZT/3TC/EFV 
[5] TDF/3TC/NVP 
[6] TDF/3TC/EFV 
[7] D4T/3TC/LPV/r 
[8] AZT/3TC/LPV/r 
[9] Other (Specify)______ 
15. Duration on initial 1st line regimen before 
modification 
    months 
HAART regimen modification history 
 
16. New regimen after modification 
 
[1] D4T/3TC/NVP 
[2] D4T/3TC/EFV 
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[3] AZT/3TC/NVP 
[4] AZT/3TC/EFV 
[5] TDF/3TC/NVP 
[6] TDF/3TC/EFV 
[7] D4T/3TC/LPV/r 
[8] AZT/3TC/LPV/r 
[9] AZT/3TC/TDF/LPVr 
[10] Other (specify) ____ 
17. If switch to 2nd line regimen: New regimen  
[1] AZT/3TC/TDF/LPVr 
[2] Other (specify) ____ 
18. Why switch to 2nd-line? 
 
[1] Clinical treatment failure 
[2] Immunologic failure 
[3] Other (specify) 
19. Reason for  HAART regimen modification  
 
[1] Toxicity 
[2] TB 
[3] New drug available 
[4] Pregnancy 
[5] TB & toxicity 
[6] Virological failure 
[7] Other reason (specify) 
Outcomes 
20. Patient status at end of study period 
 
[1] Dead 
[2] Alive  
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   APPENDIX 2 –INFORMATION SHEET  
  UNIVERSITY OF THE WESTERN CAPE 
                  School of Public Health  
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
               Tel: 021- 959 2809, Fax: 021- 959 2872 
     
 
INFORMATION SHEET 
Dear Participant 
Thank you for your willingness to hear about this research project. Below is the outline of 
the project and your potential involvement. The research is being conducted for a mini 
thesis. This is a requirement for the Masters in Public Health which l am studying at the 
University of the Western Cape. If there is anything you don’t understand or are unclear 
about, please ask me. My contact details and those of my supervisor are recorded at the 
end of this memo. 
Title of Research 
Factors associated with first line regimen modification in treatment naïve adult patients on highly 
active antiretroviral therapy at a rural clinic in Namibia 
What is this study about?  
This is a research project being conducted by Kapera Tafadzwa Justin Nyatondo, an MPH 
student at the University of the Western Cape.  We are gathering information related to factors 
associated with first line regimen modification in treatment naïve adult patients on highly active 
antiretroviral therapy (HAART) at a rural clinic in Namibia. A more detailed understanding of 
the factors associated with first line regimen modification could allow healthcare providers in 
Namibia to target these factors for intervention to reduce regime modification and improve 
treatment outcomes. 
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What will I be asked to do if I agree to participate? 
Clinic staff will be expected to assist the researcher access the electronic data required for this 
study and to help retrieve clinical records where necessary. 
Would my participation in this study be kept confidential? 
We will do our best to keep your personal information confidential.  To help protect your 
confidentiality, patient initials and identification codes will be used on data forms. Data form 
will be stored in a secure place. If we write a report or article about this research project, your 
identity will be protected to the maximum extent possible.   
What are the risks of this research? 
There are no known risks associated with participating in this research project.   
What are the benefits and costs of this research? 
You may not get any direct benefits from this study. However information generated from the 
research will allow healthcare providers in Namibia to target factors associated with treatment 
modification and help reduce regime modification and improve treatment outcomes.There are no 
costs for participating in this study other than time spent during the interview where necessary. 
Do I have to be in this research and may I stop participating at any time?   
Your participation in this research is completely voluntary.  You may choose not to take part at 
all.  If you decide to participate in this research, you may stop participating at any time.  If you 
decide not to participate in this study or if you stop participating at any time, you will not be 
penalized or lose any benefits to which you otherwise qualify. 
Informed Consent 
Your signed consent to participate in this research study is required before we proceed 
with the interview.  
What if I have questions? 
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Should you have any questions regarding this study and your rights as a research participant or if 
you wish to report any problems you have experienced related to the study, please contact me :   
 
Kapera Tafadzwa Justin Nyatondo 
Student Number: 2826494 
Cellphone 0812188292 
Work 061-310200 
E-mail nyatondojustin@hotmail.com 
 
I am accountable to my supervisor Dr Vera Scott, MD. Her contact details are  
Dr Vera Scott, MD 
University of the Western Cape 
Private Bag X17,  
Bellville 7535, South Africa 
Telephone: +27 21 959 2630 Fax: +27 21 959 2809 
email: verascott@mweb.co.za  
web: www.uwc.ac.za/publichealth 
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APPENDIX 3 -CONSENT FORM 
UNIVERSITY OF THE WESTERN CAPE 
                  School of Public Health 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
               Tel: 021- 959 2809, Fax: 021- 959 2872 
        CONSENT  FORM 
 
Title of Research Project: Factors associated with first line regimen modification in treatment 
naïve adult patients on highly active antiretroviral therapy at a rural clinic in Namibia. 
The study has been described to me in language that I understand and I freely and voluntarily 
agree to participate. My questions about the study have been answered. I understand that my 
identity will not be disclosed and that I may withdraw from the study without giving a reason at 
any time and this will not negatively affect me in any way.   
Participant’s name……………………….. 
Participant’s signature……………………………….            
Witness……………………………….            
Date……………………… 
Should you have any questions regarding this study or wish to report any problems you have 
experienced related to the study, please contact the study coordinator: 
Study Coordinator’s Name: Dr Vera Scott, MD  
University of the Western Cape 
Private Bag X17, Belville 7535, Telephone: +27 21 959 2630 Fax: +27 21 959 2809 
Email: verascott@mweb.co.za 
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APPENDIX 4 - Classes of antiretroviral agents  
Table 8: Classes of antiretroviral agents 
CLASS  MODE OF ACTION EXAMPLES 
Nucleoside Analogue 
Reverse Transcriptase 
Inhibitors (NRTIs) 
These medications inhibit the 
transcription of viral RNA 
into DNA, which is necessary for 
reproduction of the virus 
The class includes tenofovir 
(TDF), zidovudine (AZT), 
lamivudine 
(3TC), didanosine (ddI), 
stavudine (D4T), abacavir 
(ABC) and emtricitabine 
(FTC). 
Non-Nucleoside 
Reverse Transcriptase 
Inhibitors (NNRTIs) 
These medications are of a 
chemically different class 
from NRTIs, but also inhibit 
transcription of viral RNA into DNA 
The class includes nevirapine 
(NVP), efavirenz (EFV), and 
Etravirine (ETV) 
 
Protease inhibitors 
(PIs) 
Act on the viral enzyme that cuts 
long chains of virally produced 
amino acids into smaller proteins. 
The class includes lopinavir 
(LPV), indinavir (IDV), 
nelfinavir (NFV), saquinavir 
(SQV), ritonavir (RTV), 
atazanavir (ATV), 
fosamprenavir (FPV), 
tipranavir (TPV) and 
darunavir (DRV). 
Fusion inhibitors Block the virus from being able to 
merge with the host cell (i.e. CD4 
cell) after binding. 
The only currently 
available fusion inhibitor is 
enfuvirtide (ENF). 
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Intergrase inhibitors Inhibit the enzyme intergrase Raltegravir (RAL) 
CCR5 entry inhibitors Prevent HIV infection of CD4 T-
cells by blocking the CCR5 receptor 
Maraviroc (MVR) 
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APPENDIX 5 - Recommended HAART Regimens in Namibia  
Table 9: Recommended HAART regimens in Namibia 
HIV positive, ARV-naïve 
adults 
 TDF/3TC/NVP 
This is the preferred first line 
AZT/3TC/NVP  
This is the alternative preferred first line. It used if 
CD4<350 
 AZT/3TC/EFV 
This is also the alternative preferred first line. EFV is used  
if CD4>350 
HIV positive, ARV-naïve 
pregnant women 
TDF/3TC/NVP  
EFV included as an NNRTI option where CD4>350 after 
first trimester 
HIV/TB co-infection TDF/3TC/EFV 
ART is initiated as soon as possible in all HIV/TB co-
infected patients with active TB and as soon as TB treatment 
is tolerated and within 8 weeks of commencement 
HIV/HBV co-infection 
 
TDF/3TC/NVP if ALT <5 
TDF/3TC/EFV if ALT >5 
HBSAg positive clients with CD4>350 whose 
ALT is >2 x upper limit of normal (ULN) or ALT<2x ULN 
but with HBeAg positive are eligible for treatment 
regardless of WHO clinical stage. NNRTI regimens that 
contain both TDF/3TC are used 
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APPENDIX 6 - RESULTS  
Table 10: Sample size 
 Frequency % 
Total number of patients starting 1
st
 line HAART between 1
st
 
January 2007 -31
st
 December 2010 
1310 100 
Patients who had regimens modified  198 15.1% 
Patients who remained on original regimen 1112 84.9% 
 
Table 11: Age 
 Minimum Maximum Mean Standard 
deviation 
Median Skewness 
Patients who 
remained on 
original regimen 
19 83 38.8 11.14 37.5 0.875 
Patients who had 
regimens modified  
19 64 39.59 9.50 39.00 0.347 
 
Table 12:  Pre-HAART patient characteristics 
Characteristic Patients who remained on 
Original Regimen 
Patients who had 
regimens modified 
Chi 
CD4 Count n(%) 
>350 
200-350 
100-199 
50-99 
<50 
 
Frequency (Percentage) 
46 (3.8%) 
285 (23.6%) 
535 (44.3%) 
193 (16.0) 
149 (12.3%) 
Frequency  (Percentage) 
6 (3.4%) 
31 (17.4%) 
104 (58.4%) 
28 (15.7%) 
9 (5.1%) 
 
0.625 
Clinical Stage 
1 
2 
Frequency (Percentage) 
131 (10.9%) 
476 (39.4%) 
Frequency  (Percentage) 
13 (6.7%) 
80 (41.2%) 
 
0.133 
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3 
4 
 
491 (40.7%) 
109 (9.0%) 
89 (45.9%) 
12 (6.2%) 
 
 
Table 13: Duration from HIV diagnosis to enrollment into HIV general wellness care  
Duration from HIV 
diagnosis to enrollment 
into HIV general wellness 
care (months) 
Minimum Maximum Median Standard 
deviation 
p value 
Patients who remained on 
original regimen 
0 190 0 14.12 <0.0001* 
Patients who had regimens 
modified  
0 107 1 16.00 
 
Table 14: Duration from HIV diagnosis to enrollment into HIV general wellness care  
Duration in months 
Patients who remained on original 
regimens 
Patients who had 
regimens modified 
<1 657 88 
2-3 271 54 
4-6 68 12 
7-9 31 6 
10-12 24 6 
>12 84 33 
total 1134 199 
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Table 15: HAART regimens at initiation for ALL patients according to NRTI back bone 
 Remained on 
original regimen 
Later modified 
Total 
AZT based  609 90 699 
D4T based  143 96 239 
TDF based  360 12 372 
Total 1112 198 1310 
 
Table 16: HAART regimens at initiation for ALL patients according to NNRTI  choice 
  Remained on original 
regimen 
Later modified 
Total 
Patients on NVP 805 166 
971 
Patients on EFV 301 32 
333 
Total 1106 198 1304 
 
Table 17: HAART regimens for patients who remained on original regimen 
 
Frequency Percent Cumulative Percent 
AZT/3TC/EFV  99 8.9 8.9 
AZT/3TC/LPV-r  3 0.3 9.2 
AZT/3TC/NVP  507 45.6 54.8 
D4T/3TC/EFV  31 2.8 57.6 
D4T/3TC/LPV-r  1 0.1 57.7 
D4T/3TC/NVP  111 10.0 67.7 
TDF/3TC/EFV  171 15.4 83.1 
TDF/3TC/LPV 2 0.2 83.3 
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TDF/3TC/NVP  187 16.8 100.0 
Total 1112 100.0 100.0 
 
Table 18: Regimens for patients who remained on original regimen according to NRTI back bone 
 
Frequency  
Percent 
% Cumulative Percent 
AZT based  609 54.8 54.8 
D4T based  143 12.9 67.7 
TDF based  360 32.4 100.0 
Total 1112 100.0 100.0 
 
Table 19: HAART regimens for patients who remained on original regimen according to choice of NNRTI 
or PI 
 
Frequency Percent Cumulative Percent 
Patients on NVP 805 72.7 72.7 
Patients on EFV 301 27.2 100.0 
Total 1106 100.0 100.0 
 
Table 20: HAART regimens for patients who had regimens modified: BEFORE modification  
 
Frequency Percent Cumulative Percent 
AZT/3TC/EFV  13 6.6 6.6 
AZT/3TC/NVP  77 38.9 45.5 
D4T/3TC/EFV  16 8.1 53.6 
D4T/3TC/NVP  80 40.4 94.0 
TDF/3TC/EFV  3 1.5 95.5 
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TDF/3TC/NVP  9 4.5 100.0 
Total 198 100.0  
 
Table 21: HAART regimens for patients who had regimens modified: AFTER modification  
 
Frequency Percent Cumulative Percent 
ABC/3TC/LPV-r 2 1.0 1.0 
AZT/3TC/EFV  38 19.1 20.2 
AZT/3TC/LPV-r  3 1.5 21.7 
AZT/3TC/NVP  63 31.7 53.4 
D4T/3TC/EFV  18 9.0 62.6 
D4T/3TC/LVP-r 1 .5 63.1 
D4T/3TC/NVP  19 9.5 72.7 
TDF/3TC/EFV  25 12.6 85.4 
TDF/3TC/LPV-r  1 .5 85.9 
TDF/3TC/NVP  26 13.1 99.0 
TDF/AZT/3TC/LPV-r  2 1.0 100.0 
Total 198 100.0  
 
Table 22: HAART regimens for patients who had regimens modified according to NRTI choice 
 BEFORE AFTER  
 
Frequency 
n 
Perce
nt 
% 
Cumulative 
Percent 
Frequency  
n 
Percent 
% 
Cumulative 
Percent 
AZT based  90 45.5 45.5 104 52.5 52.5 
D4T based  96 48.5 94.0 38 19.2 71.7 
TDF based  12 6.1 100.0 52 26.3 98.0 
ABC based 0 0 100.0 2 1.0 99.0 
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2
nd
 line 
regimen  
0 
0 
100.0 2 1.0 100.0 
Total 198 100.0 100.0 198 100.0  
 
 
Table 23: HAART regimens for patients who had regimens modified according to choice of NNRTI or PI 
 BEFORE AFTER 
 
Frequency 
Percen
t 
Cumulative 
Percent 
Frequency  
n 
Percent 
% 
Cumulative 
Percent 
Patients on 
NVP 
166 
83.8 
83.8 108 54.5 54.5 
Patients on 
EFV 
32 
16.2 
100.0 81 40.9 95.4 
Patients on 
LPV-r 
0 
0 
100.0 7 3.5 98.9 
Second line 
regimen (4 
drugs) 
0 
0 
100.0 2 1.0 100 
Total 198 100.0 100.0 198   
 
Table 24: Pearson’s X2 test 
 
Pearson‟s X2 test P - value 
Sex 5.791 0.016* 
Marital status 6.417 0.170 
Care entry point 55.956 0.000** 
Presence of treatment supporter 2.894 0.089 
Clinical stage 5.597 0.133 
Ever put on cotrimoxazole 0.004 0.949 
Functional status 28.714 0.000** 
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Table 25: Reason for HAART Regimen Modification 
Reason for HAART Regimen 
Modification 
Frequency (Percentage) 
 
Toxicity 
TB 
New drug available 
Other 
Pregnancy 
TB & toxicity 
Virological failure 
70 (35.3%) 
54 (27.3%) 
37 (18.7%) 
16 (7.6%) 
13 (6.6%) 
5   (2.5%) 
4 (2.0%) 
 
Table 26: Cross tabulation of original first line regimen  versus  reason to change therapy  
 Reason to change therapy 
Original 
HAART 
regimen 
New 
drug 
available 
 
Virological 
failure 
 
Pregnancy 
 
TB 
 
TB & 
toxicity 
 
Toxicity 
 
Other 
 
Total 
AZT/3TC/EFV  1 0 4 0 1 5 2 13 
AZT/3TC/NVP  15 1 0 33 2 26 0 77 
D4T/3TC/EFV  6 0 5 0 0 5 0 16 
D4T/3TC/NVP  15 3 3 14 0 33 12 80 
TDF/3TC/EFV  0 0 1 0 0 1 1 3 
TDF/3TC/NVP  0 0 0 7 2 0 0 9 
Total 
37 4 13 54 5 70 15 198 
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Table 27: Regimen modification according to specific drugs 
 Stayed on  Taken off 
 n(%) n(%) 
AZT-based 39/90 (43.3) 51/90 (56.7) 
TDF-based 8/12 (66.7) 4/12 (33.3) 
D4T-based 11/97 (11.3) 86/97 (88.7) 
NVP 92/166 (55.4) 74/166 (44.6) 
EFV 14/32 (43.8) 18/32 (56.3) 
 
 
 
 
 
 
 
 
